Personal insulin pumps, continuous glucose-monitoring systems (CGMSs), and, most recently, hybrid closed-loop (HCL) systems, which are characterized by the coexistence of algorithm-driven automated insulin delivery combined with manual mealtime boluses, have had a major effect on the management of type 1 diabetes mellitus (T1DM) [2]. The gene discussed is INS; the disease is diabetes mellitus.